M. Alexandre

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 596 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Rituximab for Patients With Refractory Mucous Membrane Pemphigoid

C. Le Roux‐Villet, C. Prost‐Squarcioni, M. Alexandre et al. · Archives of Dermatology · 2011 · 146 citations · Full text

Medicine, Immunology, Pharmacotherapy +9

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

D.M. Chen, Adefowope Odueyungbo, Eva Csinady et al. · British Journal of Dermatology · 2019 · 95 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score ( <scp>ABSIS</scp> ) and Pemphigus Disease Area Index ( <scp>PDAI</scp> ) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus

C. Boulard, S. Duvert Lehembre, C. Picard‐Dahan et al. · British Journal of Dermatology · 2016 · 92 citations · Full text

Medicine, Dermatology, Autoimmunity +16

Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

Marthe Plaquevent, F. Tétart, L. Fardet et al. · Journal of Investigative Dermatology · 2018 · 85 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +4